• Dyne Therapeutics launched an underwritten public offering of USD 300 million of common stock.
• Underwriters hold a 30-day option to buy up to an additional USD 45 million of common stock.
• Morgan Stanley, Jefferies, Evercore ISI lead the deal; LifeSci Capital, Raymond James also act as bookrunners.
• Offering terms remain subject to market conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dyne Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607211646PRIMZONEFULLFEED9765930) on July 21, 2026, and is solely responsible for the information contained therein.